Financial Secretary Paul Chan Mo-po addresses the opening of the Routes World 2025 in Hong Kong on Sept 25, 2025. (PHOTO / HKSAR GOVERNMENT) Hong Kong’s financial market has performed strongly this year, with funds raised through initial public offerings reaching HK$150 billion ($19.3 billion), cementing the city’s position as the world’s top destination for…
Thirty-six biotechnology, pharmaceutical and medical device companies sought a capital raise on the Hong Kong Stock Exchange (HKEX) in the first half (H1) of 2025, a review by BioWorld found. Of those, 34 companies were from mainland China. In June alone, 12 Chinese biotechnology, pharmaceutical and med-tech companies filed for a Hong Kong IPO including…
Hong Kong’s stock market stamp duty income is filling the city’s financial coffers at the fastest pace since 2021, amid a bull run on the local bourse that has attracted scores of initial public offerings (IPOs) and fuelled frenzied trading. Duties from transactions and transfers rose to HK$29.69 billion (US$3.78 billion) in the first five…
Shein, the China-founded fast-fashion giant, is reportedly set to file a draft prospectus confidentially for an initial public offering (IPO) in Hong Kong, potentially as early as this week, according to a report in Reuters that quotes three sources familiar with the matter. The move, as per Reuters exclusive report, could make Shein one of…
Anjoy Foods Group, mainland China’s largest producer of frozen hotpot ingredients, said it plans to expand in overseas markets like Europe and Southeast Asia after it lists in Hong Kong. Liang Chen, board secretary of the Fujian-based company, told the Post that proceeds from the share sale would bolster its competitiveness in countries like Indonesia…
Eve Energy, China’s fifth-largest producer of electric vehicle (EV) batteries, plans to raise fresh capital on the Hong Kong stock exchange, following the lead of its bigger rival Contemporary Amperex Technology (CATL) as international investors show a growing appetite for the country’s industrial gems. The Shenzhen-listed company said on Tuesday that its board had endorsed…
Jiangsu Hengrui, a 55-year-old drugmaker that has become one of China’s leading forces in biotech, expects net proceeds of about 9.4 billion Hong Kong dollars … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. Source link